Skye Bioscience, Inc. (SKYE)
NASDAQ:SKYE
Want to see SKYE full AI Analyst Report?
SKYE Stock Chart & Stats
$0.79
-$0.06(-1.95%)
At close: 4:00 PM EST
$0.79
-$0.06(-1.95%)
Day’s Range― - ―
52-Week Range$0.57 - $5.75
Previous CloseN/A
Volume18.00K
Average Volume (3M)183.46K
Market Cap
$24.86M
Enterprise Value$17.17M
Total Cash (Recent Filing)$17.11M
Total Debt (Recent Filing)$311.32K
Price to Earnings (P/E)―
Beta3.21
Next Earnings
Aug 07, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding35,143,723
10 Day Avg. Volume186,961
30 Day Avg. Volume183,462
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.48
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-99.30
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$13.00Price Target Upside1545.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt reduces persistent interest and refinancing pressure and preserves flexibility during extended clinical development. For a cash-burning biotech, low leverage lowers insolvency risk and leaves strategic options (licensing, partnering, raise equity) less constrained over the next several months.
Expanded Authorized Shares And Shareholder ApprovalTripling authorized shares gives durable capital-raising and transaction flexibility without immediate dilution. With shareholder ratification and director elections, the company has structural capacity to fund trials, pursue partnerships or reshape the balance sheet as strategic needs evolve over the next 2-6 months.
Focused Clinical-stage Cannabinoid PipelineA concentrated scientific focus on CB1 receptor/metabolic disease creates a clear R&D thesis and potential differentiated assets. Clinical-stage programs provide binary development milestones that can materially de-risk value or enable licensing/partnering discussions over the medium term if trials progress.
Bears Say
No Revenue And Large Net LossesSustained operating losses without commercial revenue make the company dependent on external financing. Over a multi-month horizon this structural lack of cash-generating operations raises dilution risk and limits strategic optionality unless programs attract partners or capital quickly.
Accelerating Cash Burn And Deteriorating FCFSharp worsening of free cash flow signals accelerating cash consumption from R&D and operations. This persistent negative cash generation increases near-term funding requirements, pressures management to raise capital or cut spend, and heightens the chance of dilutive financing within 2-6 months.
Nasdaq Listing Compliance RiskSimultaneous equity and bid-price deficiencies create structural listing risk. Remedies (capital raises, reverse split, appeals) can materially alter capital structure, impose dilution, or divert management focus. Listing uncertainty can constrain strategic transactions over the medium term.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $0.56 and its highest was $5.75 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $24.86M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 48 days.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on May 11, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.309 by -$0.011.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Undervalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 35,143,723 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.309. Following the earnings report the stock price went down -7.614%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience, Inc.
Skye Bioscience, Inc. is a biopharmaceutical firm focused on the discovery, development, and commercialization of cannabinoid-based therapeutics, primarily targeting various ophthalmic conditions. The company's leading drug candidate, SBI-100, is currently undergoing Phase I clinical trials for the treatment of glaucoma and ocular hypertension. In addition, Skye Bioscience is developing SBI-200, which is in preclinical stages, to manage and treat a spectrum of eye diseases such as uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. The company, originally named Emerald Bioscience, Inc., rebranded to Skye Bioscience, Inc. in January 2021. Founded in 2012, its headquarters are situated in San Diego, California.
SKYE Company Deck
SKYE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$13.00
▲(1545.57% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
57.51% Insiders
2.73% Mutual Funds
6.38% Other Institutional Investors
31.12% Public Companies and
Individual Investors